Role of Prednisolone with Cabazitaxel
Cabazitaxel must be given with concurrent corticosteroids—specifically daily prednisone (10 mg orally) or dexamethasone on the day of chemotherapy—as this is a mandatory component of the treatment regimen for metastatic castration-resistant prostate cancer (mCRPC). 1
Rationale and Evidence Base
The requirement for concurrent corticosteroids with cabazitaxel is firmly established in the NCCN guidelines and FDA labeling, though the specific mechanism of benefit warrants discussion:
Guideline-Mandated Requirement
- NCCN 2023 guidelines explicitly state: "Cabazitaxel should be given with concurrent steroids (daily prednisone or dexamethasone on the day of chemotherapy)" 1
- The 2025 NCCN update reaffirms this requirement without modification 2
- ESMO guidelines similarly document cabazitaxel use "with prednisone or prednisolone" in their evidence tables 3
Dosing Specifications
Standard regimen:
- Prednisone 10 mg orally daily (or 5 mg twice daily) 4, 5
- Alternative: Dexamethasone on chemotherapy days 1
- This is given continuously throughout treatment, not just on infusion days
Evidence from Pivotal Trials
The landmark TROPIC trial that established cabazitaxel's survival benefit used cabazitaxel 25 mg/m² with daily prednisone as the standard regimen, demonstrating a 2.4-month overall survival improvement (HR 0.72, P<0.0001) 1, 6. All subsequent trials maintained this combination:
- PROSELICA study: Both 20 mg/m² and 25 mg/m² cabazitaxel arms included daily prednisone 1
- CARD study: Cabazitaxel "with concurrent steroid" improved radiographic PFS (8.0 vs 3.7 months, HR 0.54) 1
Pharmacokinetic Data
Critically, FDA labeling confirms: "Prednisone or prednisolone administered at 10 mg daily did not affect the pharmacokinetics of cabazitaxel" 4. This indicates the corticosteroid serves supportive rather than pharmacokinetic purposes.
Clinical Controversy: Is Prednisone Actually Necessary?
Despite guideline mandates, emerging evidence questions whether prednisone improves outcomes:
Retrospective Analysis Findings
A 2017 single-institution study (91 patients) compared cabazitaxel with versus without concurrent prednisone 7:
- No survival difference: 9 months with prednisone vs 14 months without (not statistically significant)
- No difference in PSA response rates (~45% in both groups)
- Similar safety profiles between groups
- Multivariate analysis showed prednisone use was not prognostic for overall survival
Important Caveats
However, this retrospective study has significant limitations:
- Small sample size (57 with prednisone, 34 without)
- Single-center experience
- Selection bias inherent to retrospective design
- Contradicts the universal practice in all prospective trials
Practical Clinical Approach
Despite the retrospective data suggesting prednisone may not be essential, you should continue concurrent corticosteroids with cabazitaxel for the following reasons:
Why to Continue Prednisone:
- All survival data establishing cabazitaxel's efficacy included prednisone 1, 6—deviating from this creates uncertainty about maintaining benefit
- Guideline consensus is universal across NCCN, ESMO, and ASCO [1-3]
- FDA labeling specifies the combination 4
- Minimal toxicity from low-dose prednisone (10 mg daily)
- Potential anti-inflammatory benefits in heavily pretreated patients
Additional Supportive Care Requirements
Beyond prednisone, cabazitaxel requires comprehensive prophylaxis 1, 2:
- G-CSF prophylaxis: Follow current guidelines for white blood cell growth factor support, particularly critical in this heavily pretreated, high-risk population
- Antiemetics: Prophylactic antihistamines, H2 antagonists, and corticosteroids
- Antidiarrheal agents: Symptom-directed management
Special Populations
Elderly patients (≥75 years): Prophylactic G-CSF becomes even more important, as age ≥75 years is independently associated with increased risk of grade ≥3 neutropenia 8
Common Pitfalls to Avoid
- Don't omit prednisone based solely on the single retrospective study 7—all prospective efficacy data included it
- Don't confuse the daily prednisone requirement with "on chemotherapy day only"—it's given continuously
- Don't use high-dose corticosteroids (>10 mg prednisone daily)—this may interfere with immunotherapy if later considered
- Don't forget G-CSF prophylaxis—neutropenia is the dose-limiting toxicity (grade ≥3 in 41.8-73.3% depending on dose) 1
Bottom Line
Administer cabazitaxel with concurrent prednisone 10 mg orally daily (or equivalent dexamethasone on chemotherapy days) as standard practice, following the regimen validated in all major clinical trials and mandated by current guidelines. While one retrospective study suggests prednisone may not be essential, the totality of prospective evidence and regulatory approvals support its continued use until definitive prospective data (such as the ongoing CABACARE trial mentioned in 7) demonstrate otherwise.